Ultragenyx Pharmaceutical (RARE) Other Gross PP&E Adjustments (2013 - 2025)
Ultragenyx Pharmaceutical (RARE) reported Other Gross PP&E Adjustments of $380.0 million for Q4 2025, up 0.53% year-over-year from $378.0 million in Q4 2024, and up 0.53% on a QoQ basis from $378.0 million in Q4 2024.
Ultragenyx Pharmaceutical (RARE) has 13 years of Other Gross PP&E Adjustments data on file, last reported at $380.0 million in Q4 2025.
- Quarterly Other Gross PP&E Adjustments rose 0.53% year-over-year to $380.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $380.0 million (up 0.53% YoY) and the FY2025 annual result came in at $380.0 million, up 0.53% from the prior year.
- Other Gross PP&E Adjustments advanced to $380.0 million in Q4 2025 per RARE's latest filing, from $378.0 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $380.0 million in Q4 2025 and bottomed at -$38.6 million in Q2 2021.
- The 5-year median for Other Gross PP&E Adjustments is -$24.7 million (2023), against an average of $93.6 million.
- Peak annual rise in Other Gross PP&E Adjustments reached 122.14% in 2021, while the deepest fall reached 7.49% in 2021.
- Tracing RARE's Other Gross PP&E Adjustments over 5 years: stood at $156.3 million in 2021, then jumped by 90.05% to $297.1 million in 2022, then advanced by 25.85% to $374.0 million in 2023, then climbed by 1.08% to $378.0 million in 2024, then gained by 0.53% to $380.0 million in 2025.
- Per Business Quant, the three latest RARE Other Gross PP&E Adjustments figures stand at $380.0 million (Q4 2025), $378.0 million (Q4 2024), and $374.0 million (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 380.00 Mn |
| Dec 31, 2025 | 380.00 Mn |
| Dec 31, 2024 | 378.00 Mn |
| Dec 31, 2024 | 378.00 Mn |
| Dec 31, 2023 | 373.97 Mn |
| Dec 31, 2023 | 373.97 Mn |
| Sep 30, 2023 | -26.43 Mn |
| Sep 30, 2023 | -26.43 Mn |
| Jun 30, 2023 | -19.22 Mn |
| Jun 30, 2023 | -19.22 Mn |
| Mar 31, 2023 | -22.95 Mn |
| Mar 31, 2023 | -22.95 Mn |
| Dec 31, 2022 | 297.15 Mn |
| Dec 31, 2022 | 297.15 Mn |
| Sep 30, 2022 | -28.75 Mn |
| Sep 30, 2022 | -28.75 Mn |
| Jun 30, 2022 | -31.25 Mn |
| Jun 30, 2022 | -31.25 Mn |
| Mar 31, 2022 | -32.70 Mn |
| Mar 31, 2022 | -32.70 Mn |
| Dec 31, 2021 | 156.35 Mn |
| Dec 31, 2021 | 156.35 Mn |
| Sep 30, 2021 | -36.70 Mn |
| Sep 30, 2021 | -36.70 Mn |
| Jun 30, 2021 | -38.62 Mn |
| Jun 30, 2021 | -38.62 Mn |
| Mar 31, 2021 | -38.51 Mn |
| Mar 31, 2021 | -38.51 Mn |
| Dec 31, 2020 | 70.38 Mn |
| Dec 31, 2020 | 70.38 Mn |
| Sep 30, 2020 | -37.60 Mn |
| Sep 30, 2020 | -37.60 Mn |
| Mar 31, 2020 | -35.83 Mn |
| Mar 31, 2020 | -35.83 Mn |
| Dec 31, 2019 | 40.01 Mn |
| Dec 31, 2019 | 40.01 Mn |
| Sep 30, 2019 | -31.71 Mn |
| Sep 30, 2019 | -31.71 Mn |
| Jun 30, 2019 | -33.36 Mn |
| Jun 30, 2019 | -33.36 Mn |
| Mar 31, 2019 | -23.02 Mn |
| Mar 31, 2019 | -23.02 Mn |
| Dec 31, 2018 | 38.25 Mn |
| Dec 31, 2018 | 38.25 Mn |
| Dec 31, 2017 | 32.83 Mn |
| Dec 31, 2017 | 32.83 Mn |
| Dec 31, 2016 | 23.22 Mn |
| Dec 31, 2016 | 23.22 Mn |
| Dec 31, 2015 | 10.24 Mn |
| Dec 31, 2015 | 10.24 Mn |
| Dec 31, 2014 | 4.51 Mn |
| Dec 31, 2014 | 4.51 Mn |
| Dec 31, 2013 | 2.12 Mn |
| Dec 31, 2013 | 2.12 Mn |